Objective To investigate the clinical efficacy of trigger point therapy combined with core stability training in the treatment of chronic nonspecific low back pain (CLBP). Methods Seventy-two patients with CLBP were randomly divided into control group and experimental group with 36 cases in each group. Patients in control group were treated with TDP magic lamp irradiation, The experimental group received trigger point therapy combined with core stability training on the basis of the control group, 5 times a week for 2 weeks. The total effective rate of the 2 groups was evaluated after treatment, and the visual analogue scale (VAS) and Oswestry Disability Index (ODI) scores were evaluated before and after treatment. One month after treatment, VAS score and ODI score were followed up between the two groups, and the differences in the above evaluation contents were compared. Results Before treatment, there was no significant difference in VAS score and ODI score between the two groups (P>0.05). After treatment, there were significant differences in the total effective rate, VAS score and ODI score between the two groups (P<0.05). At 1 month follow-up after treatment, the VAS score and ODI score in the group were significantly different from those before and after treatment (P<0.05), and the VAS score and ODI score were significantly different between groups (P<0.05). Conclusion Trigger point therapy combined with core stability training can reduce pain and improve lumbar function of patients with significant clinical efficacy.

Objective To establish preparation methods of ursolic acid solid dispersions and evaluate the quality in vitro. Methods Ursolic acid solid dispersions (UA-SD) were obtained with different carriers by solvent method. Based on crystal suppression experiment, the carrier materials were screened out. The dissolution rate of UA-SD with different drug loading ratio was compared by dissolution test, and the optimal UA-SD drug loading ratio was screened then the solid dispersion was identified by scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray diffraction (X-RD) and fourier transform infrared spectroscopy (FT-IR). Results Soluplus was selected as the carrier of the preparation UA-SD by crystal suppression experiments. The dissolution in vitro showed that the cumulative dissolution rate of UA-SD at 120 minute was 102.7% with a mass ratio of drug to carrier of 1:11. Solid dispersion displayed a much higher dissolution rate than raw medicine and physical mixture. The SEM, DSC, XRD and FT-IR characterizations showed that UA exist in solid dispersions in amorphous form. Conclusion Preparation of UA-SD with Soluplus as carrier can significantly increase the dissolution rate of ursolic acid.

Objective To explore the biological functions and specific molecular mechanisms of miR-638 in gastric cancer. Methods The mRNA expressions of miR-638 and MACC1 in gastric cancer cells were detected by QRT-PCR, and the protein expression of MACC1 in gastric cancer cells was detected by Western blot. The dual luciferase experiment verified the targeted binding relationship between MACC1 and miR-638. The CCK8 method was used to determine the cell proliferation activity. The scratch healing test and transwell test were used to evaluate its migration and invasion capabilities. Flow cytometry experiments to detect cell cycle distribution. Results miR-638 is down-regulated in gastric cancer cells. Overexpression of miR-638 inhibits the proliferation, migration and invasion of gastric cancer cells. MACC1 expression is significantly up-regulated in gastric cancer cells, miR-638 targets the inhibition of MACC1 expression. miR-638 inhibits the proliferation, migration and invasion of gastric cancer cells by targeted down-regulation of MACC1. Conclusion miR-638 inhibits the occurrence and development of gastric cancer cells by targeting down-regulation of MACC1.